FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Published on 29 Mar 2024 on Benzinga via Yahoo Finance

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Read the rest of the article

NASDAQ.AKBA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

New Strong Sell Stocks for January 3rd

Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today: Akebia Therapeutics, ...

Zacks · via Yahoo Finance 3 Jan 2025

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic...

Total Revenue: $43.6 million in Q2 2024. Auryxia Net Product Revenue: $41.2 million in Q2 2024,...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Revenue: Reported at $32.6 million for Q1 2024, a decrease from $40.0 million in Q1 2023, falling...

GuruFocus.com via Yahoo Finance 13 May 2024

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to s...

Simply Wall St. via Yahoo Finance 13 May 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Thera...

Insider Monkey via Yahoo Finance 11 May 2024

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

With the business potentially at an important milestone, we thought we'd take a closer look at Ak...

Simply Wall St. via Yahoo Finance 28 Apr 2024

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for...

Benzinga via Yahoo Finance 29 Mar 2024

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablet...

Zacks via Yahoo Finance 28 Mar 2024

Akebia stock jumps as FDA clears renal anemia therapy (NASDAQ:AKBA)

Akebia Therapeutics (AKBA) receives FDA approval for Vafseo tablets, leading to a 25% surge in...

Seeking Alpha 28 Mar 2024

U.S. FDA approves Akebia's anemia drug

, opens new tab drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialy...

Reuters 28 Mar 2024

News

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

NASDAQ.AKBA price evolution

Want to become a better investor?